Share Price and Basic Stock Data
Last Updated: January 6, 2026, 9:21 pm
| PEG Ratio | 1.40 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Epigral Ltd operates within the agro-chemical and pesticide sector, showcasing a robust growth trajectory. The company’s market capitalization stood at ₹5,035 Cr, with the current stock price at ₹1,167. For the fiscal year ending March 2025, Epigral reported sales of ₹2,550 Cr, a notable increase from ₹2,188 Cr in the previous year. The trailing twelve months (TTM) sales also reflected a healthy figure of ₹2,467 Cr. Quarterly revenue trends indicate fluctuations with sales of ₹651 Cr recorded in June 2024, followed by ₹626 Cr in September 2024. The company’s revenue growth is supported by a diverse product portfolio and strategic market positioning, contributing to its competitive edge in the agro-chemical sector. However, the recent decline in quarterly sales to ₹455 Cr in June 2023 raises concerns about short-term volatility.
Profitability and Efficiency Metrics
Epigral Ltd’s profitability metrics remain strong, with a reported net profit of ₹402 Cr and a return on equity (ROE) of 22.3%. The operating profit margin (OPM) for the fiscal year ended March 2025 stood at 28.46%, demonstrating effective cost management despite industry pressures. The interest coverage ratio (ICR) was impressive at 13.63x, indicating robust earnings relative to interest obligations. The company’s operating profit reached ₹711 Cr for FY 2025, reflecting operational efficiency, although it faced a decline from ₹689 Cr in FY 2023. The cash conversion cycle (CCC) was recorded at 88 days, which is relatively high compared to industry benchmarks, suggesting potential inefficiencies in inventory and receivables management. Despite these challenges, the net profit margin remained healthy at 13.98%, underscoring effective pricing strategies.
Balance Sheet Strength and Financial Ratios
Epigral Ltd’s balance sheet exhibits a solid foundation with total assets amounting to ₹3,151 Cr and total liabilities of ₹3,235 Cr as of March 2025. The company’s reserves rose to ₹2,057 Cr, highlighting retained earnings and capital accumulation. Borrowings stood at ₹537 Cr, reflecting a conservative capital structure with a debt-to-equity ratio of 0.30, indicating low financial leverage. The price-to-book value (P/BV) ratio was recorded at 4.30x, suggesting that the market values the company at a premium compared to its net assets. The return on capital employed (ROCE) stood at 25%, which is commendable and indicates efficient use of capital in generating profits. However, the increasing borrowings from ₹879 Cr in FY 2023 to ₹964 Cr in FY 2024 raise questions regarding the sustainability of this debt in the long term.
Shareholding Pattern and Investor Confidence
Epigral Ltd’s shareholding structure reflects a strong promoter presence at 68.83%, indicating significant insider commitment. Foreign institutional investors (FIIs) held 2.71%, while domestic institutional investors (DIIs) accounted for 4.93%, showing moderate institutional interest. The public shareholding stood at 23.52%, with a total of 78,605 shareholders as of September 2025. Over the past year, promoter holdings have seen a gradual decline from 71.38% in September 2023 to the current level, which could signal potential dilution of control. However, the steady increase in institutional holdings, particularly DIIs rising from 0.17% in December 2022 to 4.93% in September 2025, reflects growing investor confidence in the company’s long-term prospects. This shift may enhance liquidity and support stock price stability.
Outlook, Risks, and Final Insight
Epigral Ltd’s outlook appears cautiously optimistic, supported by a solid revenue base and strong profitability metrics. However, the company faces risks related to fluctuating sales and high operating costs, which could pressure margins. Additionally, the increasing borrowings may impact financial flexibility if not managed properly. While the agro-chemical sector has growth potential due to rising agricultural demand, regulatory challenges and competition from other players may pose threats to market share. The company’s ability to innovate and adapt to changing market dynamics will be crucial. In a favorable scenario, Epigral could leverage its strong balance sheet and operational efficiencies to capture more market share. Conversely, continued volatility in sales and rising costs might hinder growth, necessitating vigilant management strategies to navigate these challenges effectively.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Epigral Ltd | 5,035 Cr. | 1,167 | 2,114/1,151 | 12.5 | 487 | 0.51 % | 24.9 % | 22.3 % | 10.0 |
| Dharmaj Crop Guard Ltd | 810 Cr. | 240 | 391/165 | 16.6 | 131 | 0.00 % | 12.0 % | 9.28 % | 10.0 |
| Bhaskar Agrochemicals Ltd | 62.0 Cr. | 119 | 149/56.6 | 11.1 | 40.0 | 0.00 % | 21.3 % | 24.7 % | 10.0 |
| Bhagiradha Chemicals & Industries Ltd | 2,917 Cr. | 226 | 331/198 | 110 | 54.9 | 0.07 % | 7.44 % | 4.91 % | 1.00 |
| Best Agrolife Ltd | 1,016 Cr. | 430 | 598/244 | 79.4 | 342 | 0.47 % | 12.9 % | 9.95 % | 10.0 |
| Industry Average | 11,189.75 Cr | 1,129.61 | 32.29 | 382.34 | 0.43% | 15.21% | 19.87% | 7.04 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 556 | 538 | 562 | 455 | 478 | 472 | 525 | 651 | 626 | 645 | 628 | 607 | 587 |
| Expenses | 375 | 371 | 407 | 360 | 370 | 349 | 369 | 475 | 448 | 463 | 454 | 443 | 455 |
| Operating Profit | 180 | 167 | 155 | 95 | 108 | 123 | 155 | 176 | 178 | 183 | 173 | 163 | 132 |
| OPM % | 32% | 31% | 28% | 21% | 23% | 26% | 30% | 27% | 28% | 28% | 28% | 27% | 23% |
| Other Income | 2 | -0 | 5 | 2 | 1 | 2 | 2 | 2 | 6 | 4 | 3 | 8 | 2 |
| Interest | 14 | 21 | 19 | 18 | 21 | 20 | 14 | 14 | 27 | -0 | 12 | 23 | 22 |
| Depreciation | 26 | 31 | 30 | 31 | 32 | 31 | 30 | 33 | 32 | 33 | 34 | 42 | 42 |
| Profit before tax | 142 | 114 | 110 | 48 | 56 | 74 | 113 | 131 | 124 | 154 | 131 | 107 | 70 |
| Tax % | 35% | 33% | 30% | 33% | 32% | 34% | 32% | 34% | 35% | 33% | 34% | -50% | 26% |
| Net Profit | 92 | 77 | 77 | 32 | 38 | 49 | 77 | 86 | 81 | 104 | 87 | 160 | 52 |
| EPS in Rs | 22.04 | 18.58 | 18.48 | 7.62 | 9.18 | 11.87 | 18.45 | 20.70 | 19.38 | 24.00 | 20.08 | 37.18 | 11.94 |
Last Updated: December 27, 2025, 2:06 am
Below is a detailed analysis of the quarterly data for Epigral Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 587.00 Cr.. The value appears to be declining and may need further review. It has decreased from 607.00 Cr. (Jun 2025) to 587.00 Cr., marking a decrease of 20.00 Cr..
- For Expenses, as of Sep 2025, the value is 455.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 443.00 Cr. (Jun 2025) to 455.00 Cr., marking an increase of 12.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 132.00 Cr.. The value appears to be declining and may need further review. It has decreased from 163.00 Cr. (Jun 2025) to 132.00 Cr., marking a decrease of 31.00 Cr..
- For OPM %, as of Sep 2025, the value is 23.00%. The value appears to be declining and may need further review. It has decreased from 27.00% (Jun 2025) to 23.00%, marking a decrease of 4.00%.
- For Other Income, as of Sep 2025, the value is 2.00 Cr.. The value appears to be declining and may need further review. It has decreased from 8.00 Cr. (Jun 2025) to 2.00 Cr., marking a decrease of 6.00 Cr..
- For Interest, as of Sep 2025, the value is 22.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 23.00 Cr. (Jun 2025) to 22.00 Cr., marking a decrease of 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 42.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 42.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 70.00 Cr.. The value appears to be declining and may need further review. It has decreased from 107.00 Cr. (Jun 2025) to 70.00 Cr., marking a decrease of 37.00 Cr..
- For Tax %, as of Sep 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from -50.00% (Jun 2025) to 26.00%, marking an increase of 76.00%.
- For Net Profit, as of Sep 2025, the value is 52.00 Cr.. The value appears to be declining and may need further review. It has decreased from 160.00 Cr. (Jun 2025) to 52.00 Cr., marking a decrease of 108.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 11.94. The value appears to be declining and may need further review. It has decreased from 37.18 (Jun 2025) to 11.94, marking a decrease of 25.24.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:46 am
| Metric | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 394 | 392 | 598 | 710 | 611 | 829 | 1,551 | 2,188 | 1,929 | 2,550 | 2,467 |
| Expenses | 245 | 248 | 346 | 405 | 416 | 567 | 1,041 | 1,499 | 1,448 | 1,839 | 1,815 |
| Operating Profit | 149 | 144 | 252 | 306 | 194 | 261 | 510 | 689 | 481 | 711 | 652 |
| OPM % | 38% | 37% | 42% | 43% | 32% | 32% | 33% | 31% | 25% | 28% | 26% |
| Other Income | 2 | 1 | 8 | 16 | 2 | 2 | 4 | 8 | 6 | 15 | 17 |
| Interest | 19 | 14 | 9 | 25 | 11 | 29 | 44 | 66 | 73 | 53 | 57 |
| Depreciation | 44 | 55 | 55 | 54 | 44 | 74 | 86 | 109 | 124 | 133 | 151 |
| Profit before tax | 88 | 75 | 195 | 242 | 141 | 161 | 383 | 523 | 291 | 540 | 461 |
| Tax % | 23% | 11% | 20% | 25% | 21% | 37% | 34% | 32% | 33% | 34% | |
| Net Profit | 67 | 67 | 155 | 183 | 112 | 101 | 253 | 353 | 196 | 357 | 402 |
| EPS in Rs | 9.49 | 9.40 | 21.97 | 44.38 | 27.19 | 24.48 | 60.84 | 85.04 | 47.12 | 82.68 | 93.20 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 6% | 11% | 7% |
YoY Net Profit Growth
| Year | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 131.34% | 18.06% | -38.80% | -9.82% | 150.50% | 39.53% | -44.48% | 82.14% |
| Change in YoY Net Profit Growth (%) | 0.00% | 131.34% | -113.28% | -56.86% | 28.98% | 160.32% | -110.97% | -84.00% | 126.62% |
Epigral Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2016-2017 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 33% |
| 3 Years: | 18% |
| TTM: | 18% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 26% |
| 3 Years: | 12% |
| TTM: | 72% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 7% |
| 1 Year: | -5% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 27% |
| 3 Years: | 25% |
| Last Year: | 22% |
Last Updated: September 5, 2025, 3:26 pm
Balance Sheet
Last Updated: December 10, 2025, 4:16 am
| Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 71 | 71 | 71 | 41 | 42 | 42 | 42 | 42 | 42 | 43 | 43 |
| Reserves | 224 | 291 | 447 | 241 | 331 | 432 | 684 | 1,028 | 1,213 | 1,860 | 2,057 |
| Borrowings | 190 | 123 | 74 | 601 | 737 | 753 | 993 | 879 | 964 | 593 | 537 |
| Other Liabilities | 55 | 42 | 79 | 162 | 164 | 223 | 405 | 484 | 576 | 655 | 598 |
| Total Liabilities | 540 | 527 | 671 | 1,044 | 1,273 | 1,449 | 2,124 | 2,432 | 2,794 | 3,151 | 3,235 |
| Fixed Assets | 364 | 398 | 347 | 295 | 440 | 1,102 | 1,068 | 1,804 | 1,767 | 2,238 | 2,176 |
| CWIP | 69 | 3 | 79 | 468 | 691 | 126 | 589 | 158 | 483 | 64 | 309 |
| Investments | -0 | 29 | 71 | -0 | -0 | 0 | 0 | 21 | 21 | 97 | 44 |
| Other Assets | 106 | 98 | 173 | 281 | 142 | 221 | 467 | 449 | 524 | 752 | 707 |
| Total Assets | 540 | 527 | 671 | 1,044 | 1,273 | 1,449 | 2,124 | 2,432 | 2,794 | 3,151 | 3,235 |
Below is a detailed analysis of the balance sheet data for Epigral Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 43.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 43.00 Cr..
- For Reserves, as of Sep 2025, the value is 2,057.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,860.00 Cr. (Mar 2025) to 2,057.00 Cr., marking an increase of 197.00 Cr..
- For Borrowings, as of Sep 2025, the value is 537.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 593.00 Cr. (Mar 2025) to 537.00 Cr., marking a decrease of 56.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 598.00 Cr.. The value appears to be improving (decreasing). It has decreased from 655.00 Cr. (Mar 2025) to 598.00 Cr., marking a decrease of 57.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 3,235.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,151.00 Cr. (Mar 2025) to 3,235.00 Cr., marking an increase of 84.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 2,176.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,238.00 Cr. (Mar 2025) to 2,176.00 Cr., marking a decrease of 62.00 Cr..
- For CWIP, as of Sep 2025, the value is 309.00 Cr.. The value appears strong and on an upward trend. It has increased from 64.00 Cr. (Mar 2025) to 309.00 Cr., marking an increase of 245.00 Cr..
- For Investments, as of Sep 2025, the value is 44.00 Cr.. The value appears to be declining and may need further review. It has decreased from 97.00 Cr. (Mar 2025) to 44.00 Cr., marking a decrease of 53.00 Cr..
- For Other Assets, as of Sep 2025, the value is 707.00 Cr.. The value appears to be declining and may need further review. It has decreased from 752.00 Cr. (Mar 2025) to 707.00 Cr., marking a decrease of 45.00 Cr..
- For Total Assets, as of Sep 2025, the value is 3,235.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,151.00 Cr. (Mar 2025) to 3,235.00 Cr., marking an increase of 84.00 Cr..
Notably, the Reserves (2,057.00 Cr.) exceed the Borrowings (537.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -41.00 | 21.00 | 178.00 | -295.00 | -543.00 | -492.00 | -483.00 | -190.00 | -483.00 | 118.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 43 | 41 | 47 | 40 | 46 | 52 | 60 | 28 | 34 | 33 |
| Inventory Days | 75 | 59 | 45 | 58 | 64 | 51 | 74 | 69 | 90 | 105 |
| Days Payable | 31 | 37 | 51 | 52 | 62 | 69 | 42 | 36 | 63 | 50 |
| Cash Conversion Cycle | 86 | 63 | 42 | 46 | 48 | 34 | 92 | 61 | 61 | 88 |
| Working Capital Days | 43 | 40 | 19 | -27 | -76 | -92 | -26 | -41 | -54 | 26 |
| ROCE % | 18% | 37% | 36% | 15% | 16% | 29% | 32% | 17% | 25% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HSBC Value Fund | 494,874 | 0.51 | 74.81 | N/A | N/A | N/A |
| Bandhan Small Cap Fund | 459,048 | 0.38 | 69.39 | 403,705 | 2025-12-15 06:52:35 | 13.71% |
| HSBC Focused Fund | 250,650 | 2.2 | 37.89 | N/A | N/A | N/A |
| HSBC Flexi Cap Fund | 213,965 | 0.62 | 32.35 | N/A | N/A | N/A |
| HSBC ELSS Tax saver Fund | 121,645 | 0.44 | 18.39 | N/A | N/A | N/A |
| HSBC Business Cycles Fund | 76,350 | 1 | 11.54 | N/A | N/A | N/A |
| HSBC Tax Saver Equity Fund | 17,300 | 1.06 | 2.62 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 84.68 | 47.14 | 85.03 | 60.84 | 24.27 |
| Diluted EPS (Rs.) | 84.68 | 47.14 | 85.03 | 60.84 | 24.27 |
| Cash EPS (Rs.) | 113.41 | 76.87 | 111.25 | 81.51 | 41.97 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 441.48 | 301.83 | 257.30 | 174.72 | 113.88 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 441.48 | 301.83 | 257.30 | 174.72 | 113.88 |
| Revenue From Operations / Share (Rs.) | 591.13 | 464.30 | 526.69 | 373.27 | 199.41 |
| PBDIT / Share (Rs.) | 168.27 | 117.39 | 167.73 | 123.61 | 63.42 |
| PBIT / Share (Rs.) | 137.54 | 87.66 | 141.51 | 102.93 | 45.72 |
| PBT / Share (Rs.) | 125.20 | 69.97 | 125.75 | 92.28 | 38.71 |
| Net Profit / Share (Rs.) | 82.68 | 47.13 | 85.03 | 60.84 | 24.27 |
| NP After MI And SOA / Share (Rs.) | 82.91 | 47.14 | 85.03 | 60.84 | 24.27 |
| PBDIT Margin (%) | 28.46 | 25.28 | 31.84 | 33.11 | 31.80 |
| PBIT Margin (%) | 23.26 | 18.87 | 26.86 | 27.57 | 22.92 |
| PBT Margin (%) | 21.17 | 15.06 | 23.87 | 24.72 | 19.41 |
| Net Profit Margin (%) | 13.98 | 10.15 | 16.14 | 16.29 | 12.16 |
| NP After MI And SOA Margin (%) | 14.02 | 10.15 | 16.14 | 16.29 | 12.16 |
| Return on Networth / Equity (%) | 18.78 | 15.61 | 33.04 | 34.82 | 21.30 |
| Return on Capital Employeed (%) | 22.30 | 18.07 | 32.94 | 26.87 | 17.92 |
| Return On Assets (%) | 11.34 | 7.00 | 14.52 | 11.90 | 6.96 |
| Long Term Debt / Equity (X) | 0.23 | 0.39 | 0.40 | 1.06 | 0.71 |
| Total Debt / Equity (X) | 0.30 | 0.72 | 0.71 | 1.36 | 0.87 |
| Asset Turnover Ratio (%) | 0.85 | 0.73 | 0.96 | 0.86 | 0.00 |
| Current Ratio (X) | 1.57 | 0.64 | 0.64 | 0.83 | 0.46 |
| Quick Ratio (X) | 0.78 | 0.30 | 0.32 | 0.55 | 0.32 |
| Inventory Turnover Ratio (X) | 7.83 | 4.51 | 6.62 | 7.30 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 8.82 | 5.30 | 2.94 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 6.43 | 3.25 | 2.24 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 91.18 | 94.70 | 97.06 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 93.57 | 96.75 | 97.76 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 13.63 | 6.64 | 10.64 | 11.60 | 9.05 |
| Interest Coverage Ratio (Post Tax) (X) | 7.70 | 3.66 | 6.39 | 6.71 | 4.46 |
| Enterprise Value (Cr.) | 8753.81 | 5509.59 | 4780.47 | 5010.23 | 0.00 |
| EV / Net Operating Revenue (X) | 3.43 | 2.86 | 2.18 | 3.23 | 0.00 |
| EV / EBITDA (X) | 12.06 | 11.30 | 6.86 | 9.76 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 3.21 | 2.36 | 1.79 | 2.61 | 0.00 |
| Retention Ratios (%) | 91.17 | 94.69 | 97.05 | 0.00 | 0.00 |
| Price / BV (X) | 4.30 | 3.63 | 3.67 | 5.57 | 0.00 |
| Price / Net Operating Revenue (X) | 3.21 | 2.36 | 1.79 | 2.61 | 0.00 |
| EarningsYield | 0.04 | 0.04 | 0.09 | 0.06 | 0.00 |
After reviewing the key financial ratios for Epigral Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 84.68. This value is within the healthy range. It has increased from 47.14 (Mar 24) to 84.68, marking an increase of 37.54.
- For Diluted EPS (Rs.), as of Mar 25, the value is 84.68. This value is within the healthy range. It has increased from 47.14 (Mar 24) to 84.68, marking an increase of 37.54.
- For Cash EPS (Rs.), as of Mar 25, the value is 113.41. This value is within the healthy range. It has increased from 76.87 (Mar 24) to 113.41, marking an increase of 36.54.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 441.48. It has increased from 301.83 (Mar 24) to 441.48, marking an increase of 139.65.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 441.48. It has increased from 301.83 (Mar 24) to 441.48, marking an increase of 139.65.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 591.13. It has increased from 464.30 (Mar 24) to 591.13, marking an increase of 126.83.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 168.27. This value is within the healthy range. It has increased from 117.39 (Mar 24) to 168.27, marking an increase of 50.88.
- For PBIT / Share (Rs.), as of Mar 25, the value is 137.54. This value is within the healthy range. It has increased from 87.66 (Mar 24) to 137.54, marking an increase of 49.88.
- For PBT / Share (Rs.), as of Mar 25, the value is 125.20. This value is within the healthy range. It has increased from 69.97 (Mar 24) to 125.20, marking an increase of 55.23.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 82.68. This value is within the healthy range. It has increased from 47.13 (Mar 24) to 82.68, marking an increase of 35.55.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 82.91. This value is within the healthy range. It has increased from 47.14 (Mar 24) to 82.91, marking an increase of 35.77.
- For PBDIT Margin (%), as of Mar 25, the value is 28.46. This value is within the healthy range. It has increased from 25.28 (Mar 24) to 28.46, marking an increase of 3.18.
- For PBIT Margin (%), as of Mar 25, the value is 23.26. This value exceeds the healthy maximum of 20. It has increased from 18.87 (Mar 24) to 23.26, marking an increase of 4.39.
- For PBT Margin (%), as of Mar 25, the value is 21.17. This value is within the healthy range. It has increased from 15.06 (Mar 24) to 21.17, marking an increase of 6.11.
- For Net Profit Margin (%), as of Mar 25, the value is 13.98. This value exceeds the healthy maximum of 10. It has increased from 10.15 (Mar 24) to 13.98, marking an increase of 3.83.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 14.02. This value is within the healthy range. It has increased from 10.15 (Mar 24) to 14.02, marking an increase of 3.87.
- For Return on Networth / Equity (%), as of Mar 25, the value is 18.78. This value is within the healthy range. It has increased from 15.61 (Mar 24) to 18.78, marking an increase of 3.17.
- For Return on Capital Employeed (%), as of Mar 25, the value is 22.30. This value is within the healthy range. It has increased from 18.07 (Mar 24) to 22.30, marking an increase of 4.23.
- For Return On Assets (%), as of Mar 25, the value is 11.34. This value is within the healthy range. It has increased from 7.00 (Mar 24) to 11.34, marking an increase of 4.34.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.23. This value is within the healthy range. It has decreased from 0.39 (Mar 24) to 0.23, marking a decrease of 0.16.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.30. This value is within the healthy range. It has decreased from 0.72 (Mar 24) to 0.30, marking a decrease of 0.42.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.85. It has increased from 0.73 (Mar 24) to 0.85, marking an increase of 0.12.
- For Current Ratio (X), as of Mar 25, the value is 1.57. This value is within the healthy range. It has increased from 0.64 (Mar 24) to 1.57, marking an increase of 0.93.
- For Quick Ratio (X), as of Mar 25, the value is 0.78. This value is below the healthy minimum of 1. It has increased from 0.30 (Mar 24) to 0.78, marking an increase of 0.48.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 7.83. This value is within the healthy range. It has increased from 4.51 (Mar 24) to 7.83, marking an increase of 3.32.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 8.82. This value is below the healthy minimum of 20. It has increased from 5.30 (Mar 24) to 8.82, marking an increase of 3.52.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 6.43. This value is below the healthy minimum of 20. It has increased from 3.25 (Mar 24) to 6.43, marking an increase of 3.18.
- For Earning Retention Ratio (%), as of Mar 25, the value is 91.18. This value exceeds the healthy maximum of 70. It has decreased from 94.70 (Mar 24) to 91.18, marking a decrease of 3.52.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 93.57. This value exceeds the healthy maximum of 70. It has decreased from 96.75 (Mar 24) to 93.57, marking a decrease of 3.18.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 13.63. This value is within the healthy range. It has increased from 6.64 (Mar 24) to 13.63, marking an increase of 6.99.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.70. This value is within the healthy range. It has increased from 3.66 (Mar 24) to 7.70, marking an increase of 4.04.
- For Enterprise Value (Cr.), as of Mar 25, the value is 8,753.81. It has increased from 5,509.59 (Mar 24) to 8,753.81, marking an increase of 3,244.22.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.43. This value exceeds the healthy maximum of 3. It has increased from 2.86 (Mar 24) to 3.43, marking an increase of 0.57.
- For EV / EBITDA (X), as of Mar 25, the value is 12.06. This value is within the healthy range. It has increased from 11.30 (Mar 24) to 12.06, marking an increase of 0.76.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.21. This value exceeds the healthy maximum of 3. It has increased from 2.36 (Mar 24) to 3.21, marking an increase of 0.85.
- For Retention Ratios (%), as of Mar 25, the value is 91.17. This value exceeds the healthy maximum of 70. It has decreased from 94.69 (Mar 24) to 91.17, marking a decrease of 3.52.
- For Price / BV (X), as of Mar 25, the value is 4.30. This value exceeds the healthy maximum of 3. It has increased from 3.63 (Mar 24) to 4.30, marking an increase of 0.67.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.21. This value exceeds the healthy maximum of 3. It has increased from 2.36 (Mar 24) to 3.21, marking an increase of 0.85.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Epigral Ltd:
- Net Profit Margin: 13.98%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 22.3% (Industry Average ROCE: 15.21%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 18.78% (Industry Average ROE: 19.87%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 7.7
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.78
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 12.5 (Industry average Stock P/E: 32.29)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.3
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 13.98%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Agro Chemicals/Pesticides | �Epigral Tower�, Behind Safal Profitaire, Ahmedabad Gujarat 380015 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Maulik Patel | Chairman & Managing Director |
| Mr. Kaushal Soparkar | Executive Director |
| Mr. Ankit Patel | Non Exe.Non Ind.Director |
| Mr. Karana Patel | Non Exe.Non Ind.Director |
| Mr. Darshan Patel | Non Exe.Non Ind.Director |
| Mr. Manubhai Patel | Independent Director |
| Mr. Sanjay Asher | Independent Director |
| Mr. Kanubhai Patel | Independent Director |
| Mr. Raju Swamy | Independent Director |
| Ms. Priyanka Chopra | Independent Woman Director |
FAQ
What is the intrinsic value of Epigral Ltd?
Epigral Ltd's intrinsic value (as of 07 January 2026) is ₹1091.55 which is 6.47% lower the current market price of ₹1,167.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹5,035 Cr. market cap, FY2025-2026 high/low of ₹2,114/1,151, reserves of ₹2,057 Cr, and liabilities of ₹3,235 Cr.
What is the Market Cap of Epigral Ltd?
The Market Cap of Epigral Ltd is 5,035 Cr..
What is the current Stock Price of Epigral Ltd as on 07 January 2026?
The current stock price of Epigral Ltd as on 07 January 2026 is ₹1,167.
What is the High / Low of Epigral Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Epigral Ltd stocks is ₹2,114/1,151.
What is the Stock P/E of Epigral Ltd?
The Stock P/E of Epigral Ltd is 12.5.
What is the Book Value of Epigral Ltd?
The Book Value of Epigral Ltd is 487.
What is the Dividend Yield of Epigral Ltd?
The Dividend Yield of Epigral Ltd is 0.51 %.
What is the ROCE of Epigral Ltd?
The ROCE of Epigral Ltd is 24.9 %.
What is the ROE of Epigral Ltd?
The ROE of Epigral Ltd is 22.3 %.
What is the Face Value of Epigral Ltd?
The Face Value of Epigral Ltd is 10.0.